106 related articles for article (PubMed ID: 9768682)
1. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.
Narimatsu M; Nagayama Y; Akino K; Yasuda M; Yamamoto T; Yang TT; Ohtsuru A; Namba H; Yamashita S; Ayabe H; Niwa M
J Clin Endocrinol Metab; 1998 Oct; 83(10):3668-72. PubMed ID: 9768682
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo.
Nagayama Y; Yokoi H; Takeda K; Hasegawa M; Nishihara E; Namba H; Yamashita S; Niwa M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4081-6. PubMed ID: 11095436
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo.
Nagayama Y; Shigematsu K; Namba H; Zeki K; Yamashita S; Niwa M
Anticancer Res; 2000; 20(4):2723-8. PubMed ID: 10953350
[TBL] [Abstract][Full Text] [Related]
4. p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells.
Yang T; Namba H; Hara T; Takmura N; Nagayama Y; Fukata S; Ishikawa N; Kuma K; Ito K; Yamashita S
Oncogene; 1997 Apr; 14(13):1511-9. PubMed ID: 9129141
[TBL] [Abstract][Full Text] [Related]
5. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status.
Moretti F; Nanni S; Farsetti A; Narducci M; Crescenzi M; Giuliacci S; Sacchi A; Pontecorvi A
J Clin Endocrinol Metab; 2000 Jan; 85(1):302-8. PubMed ID: 10634403
[TBL] [Abstract][Full Text] [Related]
6. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.
Moretti F; Farsetti A; Soddu S; Misiti S; Crescenzi M; Filetti S; Andreoli M; Sacchi A; Pontecorvi A
Oncogene; 1997 Feb; 14(6):729-40. PubMed ID: 9038381
[TBL] [Abstract][Full Text] [Related]
7. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells.
Blagosklonny MV; Giannakakou P; Wojtowicz M; Romanova LY; Ain KB; Bates SE; Fojo T
J Clin Endocrinol Metab; 1998 Jul; 83(7):2516-22. PubMed ID: 9661637
[TBL] [Abstract][Full Text] [Related]
8. Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.
Fricke E; Hermannstädter C; Keller G; Fuchs M; Brunner I; Busch R; Höfler H; Becker KF; Luber B
Oncology; 2004; 66(2):150-9. PubMed ID: 15138368
[TBL] [Abstract][Full Text] [Related]
9. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
10. Modulation of retrovirally driven therapeutic genes by mutant TP53 in anaplastic thyroid carcinoma.
Barzon L; Gnatta E; Castagliuolo I; Trevisan M; Moretti F; Pontecorvi A; Boscaro M; Palù G
Cancer Gene Ther; 2005 Apr; 12(4):381-8. PubMed ID: 15650765
[TBL] [Abstract][Full Text] [Related]
11. Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system.
Nagayama Y; Nishihara E; Namba H; Yokoi H; Hasegawa M; Mizuguchi H; Hayakawa T; Hamada H; Yamashita S; Niwa M
Cancer Gene Ther; 2001 Jan; 8(1):36-44. PubMed ID: 11219492
[TBL] [Abstract][Full Text] [Related]
12. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
Portella G; Scala S; Vitagliano D; Vecchio G; Fusco A
J Clin Endocrinol Metab; 2002 Jun; 87(6):2525-31. PubMed ID: 12050209
[TBL] [Abstract][Full Text] [Related]
13. Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas.
Lavra L; Ulivieri A; Rinaldo C; Dominici R; Volante M; Luciani E; Bartolazzi A; Frasca F; Soddu S; Sciacchitano S
J Pathol; 2009 May; 218(1):66-75. PubMed ID: 19199318
[TBL] [Abstract][Full Text] [Related]
14. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
[TBL] [Abstract][Full Text] [Related]
15. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
16. CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Horm Metab Res; 2013 Jan; 45(1):9-14. PubMed ID: 22918703
[TBL] [Abstract][Full Text] [Related]
17. Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis.
Asakawa H; Kobayashi T; Komoike Y; Yanagawa T; Takahashi M; Wakasugi E; Maruyama H; Tamaki Y; Matsuzawa Y; Monden M
J Clin Endocrinol Metab; 1996 Oct; 81(10):3547-52. PubMed ID: 8855799
[TBL] [Abstract][Full Text] [Related]
18. Involvement of wild-type p53 in radiation-induced c-Jun N-terminal kinase activation in human thyroid cells.
Shklyaev SS; Namba H; Sautin Y; Mitsutake N; Nagayama Y; Ishikawa N; Ito K; Zeki K; Yamashita S
Anticancer Res; 2001; 21(4A):2569-75. PubMed ID: 11724323
[TBL] [Abstract][Full Text] [Related]
19. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
20. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
